Key result
Enalapril slowed the progression of chronic nephropathy compared to conventional therapy, with a median GFR decline of -0.20 vs -0.31 mL/min/1.73 m2/month (P<0.05).
Why the study?
Does enalapril reduce the progression of chronic nephropathy in patients with moderate to severe chronic renal failure compared to conventional antihypertensive treatment?
Population
70 patients with chronic nephropathy with a median GFR of 15 mL/min/1.73 m2
Comparison
Basic treatment with enalapril vs Conventional antihypertensive treatment
Design
RCT, Randomized, Open study
Follow-up
At least 2 years or until they needed dialysis
Authors
Loading...
Supports enalapril to slow GFR decline in moderate-severe chronic nephropathy; confirms ACE inhibitor benefit on CKD progression.
RCT (n=70)
Open-label
Does enalapril reduce the progression of chronic nephropathy in patients with moderate to severe chronic renal failure compared to conventional antihypertensive treatment?
Absolute Event Rate: -0.2% vs -0.31%
p-value: p=<0.05
Enalapril significantly slows the decline of glomerular filtration rate in patients with moderate to severe chronic nephropathy compared to conventional antihypertensive therapy.
Kamper et al. (1992) conducted an RCT in Chronic renal failure (n=70). Enalapril vs. Conventional antihypertensive treatment was evaluated on Median decline in GFR (mL/min/1.73 m2/month) (p=<0.05). Enalapril slowed the progression of chronic nephropathy compared to conventional therapy, with a median GFR decline of -0.20 vs -0.31 mL/min/1.73 m2/month (P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: